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Aims The aim is to make a systematic review of the literature to assess the effect of lipid-lowering drugs on venous
thromboembolism (VTE) occurrence.
Methods
and results
MEDLINE and EMBASE databases were searched to identify studies that evaluated the effect of lipid-lowering drugs,
in particular statins and fibrates, on VTE risk until April 2009. A scoring system was used to divide studies into two
quality categories. Odds ratios (ORs) and 95% confidence intervals (CIs) were then calculated and pooled using a
fixed and a random-effects model. Statistical heterogeneity was evaluated through the use of I2 statistics. Three ran-
domized controlled trials (RCTs), three cohort, and eight case–control studies were included in our systematic
review, for a total of 863 805 patients. Statins use significantly reduced VTE risk [OR, 0.81; 95% CI, 0.66–0.99,
random-effect model)]. There was a very high heterogeneity among the studies (I2. 80%). The use of fibrates
was associated with a significant increase in the risk of VTE (OR, 1.58; 95% CI, 1.23–2.02), without heterogeneity
(I2 ¼ 0%). Data on other lipid-lowering drugs were lacking.
Conclusion This meta-analysis of available literature suggests that statins may lower the risk of VTE, whereas fibrates may increase
this risk. Due to several methodological limitations, this conclusion should be considered with caution, and additional,
specifically designed RCTs are warranted.
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Introduction
Lipid-lowering drugs are a wide group of molecules including the
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
(statins), fibrates, cholesterol absorption inhibitors, bile acid
sequestrants, niacin, and fish oil. They are widely used in the man-
agement of patients with hyperlipidaemia and in the primary and
secondary prevention of atherosclerotic disease.1 Several bio-
chemical effects have been advocated in addition to modifying
lipid profile.2 Among them, interactions with the haemostatic
system and with antithrombotic drugs have been described, but
the clinical relevance of these properties is still unclear.3 Observa-
tional studies have reported a reduced risk for venous throm-
boembolism (VTE), i.e. deep venous thrombosis (DVT) and
pulmonary embolism (PE), in patients on statins treatment
and an increased risk for VTE in patients on fibrates
treatment.4 Although this effect, if true, may be associated with a
modified lipid profile, the hypothesis of a clinically relevant role
of lipid-lowering drugs on the coagulation system remains
intriguing.5
The primary aim of our systematic review was to assess the
effect of lipid-lowering drugs, in particular statins and fibrates, on
the risk of VTE.
Methods
Study identification
We attempted to identify all published studies that evaluated the effects
of lipid-lowering drugs on VTE risk using the MEDLINE (1966 to April
Week 1 2009) and EMBASE (1980 to April Week 2 2009) electronic
databases. The following search terms (textwords and MeSH or
EMTREE terms, respectively) were used for the MEDLINE search:
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anticholesteremic
Agents, Clofibric Acid, Antilipemic Agents, Statins, Fibrates, Embolism
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and Thrombosis, Venous Thromboembolism, Vein Thrombosis; and for
the EMBASE database search: Hydroxymethylglutaryl Coenzyme
A Reductase Inhibitor, Ezetimibe, Fibric Acid, Antilipemic Agent,
Omega 3 Fatty Acid, Vein thrombosis, Venous Thromboembolism.
The search strategy was developed without any language restriction.
Reference lists of all studies included in the present systematic review
were screened for potential additional eligible studies. A letter and/or
e-mail were sent to the corresponding author if the full manuscript was
unavailable.
Study selection
Two authors (M.G., E.R.) independently reviewed all selected titles and
abstracts. Studies were excluded if the title and/or abstract was not
appropriate for the aim of our review. Full texts were subsequently
obtained for eligible studies or when the relevance of an article
could not be excluded with certainty. Disagreement was resolved by
consensus and by opinion of a third reviewer (A.S.), if necessary.
Selected studies were eligible if they met the following criteria: patients
were 18 years or older and at least 100 patients were enrolled. Both
observational and experimental studies were included. Reviews, case-
reports, and non-human studies were excluded.
Data extraction and quality assessment
For randomized controlled trials (RCTs), we planned quality assess-
ment by means of Jadad’s scale, which evaluates the following three
study characteristics: method of randomization, method of blinding,
and follow-up.6 To stratify RCTs, we applied the following cut-offs: a
total of five points defined high quality studies; three and four points
defined medium quality studies; two or less points defined low
quality studies.
Although in observational studies the use of quality scoring systems
or quality scales is controversial,7 study quality was assessed by the fol-
lowing items for cohort studies: type of study (prospective or retro-
spective); patient selection (consecutive patients without potential
bias of selection); control group (consecutive enrolment or matched
for age and sex). For each fulfilled item one point was given.
A scoring system was adapted to identify three quality categories as
follows: a total of three points defined high quality studies; two or
less point defined low quality studies. The total number of patients
lost to follow-up (less than 5% of patients, more than 20%, or
between 5 and 20%) was also ascertained as an additional quality
item. For case–control studies, the following items assessed study
quality: patient selection (consecutive patients without potential bias
of selection); control group (consecutive enrolment or matched for
age and sex). A total of two points defined high-quality studies; one
or less defined a low-quality study. The total number of cases was
also ascertained as an additional quality item.
One reviewer (M.G.) completed the data extraction form. A second
reviewer (A.S.) checked the extracted data. The following character-
istics were collected: (i) total number of enrolled patients; (ii)
follow-up duration for RCTs and cohort studies; (iii) VTE diagnosis
(objective or clinical); (iv) inclusion or exclusion or patients with pre-
vious VTE; (v) type of lipid-lowering drugs; (vi) molecule and dosage;
(vii) use of lipid-lowering drugs for primary or secondary prevention
of cardiovascular diastase; (viii) outcomes: for RCTs and cohort
studies these included total VTE events, DVT, and PE; for case–
control studies, the use of any lipid-lowering drugs. In case data
were available for both current and past lipid-lowering drug use, we
included in the meta-analysis only current use. Corresponding
author was contacted for additional data in case absolute values
were not provided in the manuscript.
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.
These data were pooled using a fixed-effects model (the Mantel–
Haenszel method),8 and comparing these findings with the results
obtained using a random-effects model (the DerSimionan and Laird
method), in particular in case of significant statistical heterogeneity.9
In case of high statistical heterogeneity, results using random-effects
model are reported. Statistical heterogeneity was evaluated using the
I2 statistic, which assesses the appropriateness of pooling the individual
study results.10 The I2 value provides an estimate of the amount of var-
iance across studies due to heterogeneity rather than chance. I2 , 30%
indicates mild heterogeneity, 30–50% moderate, and .50% severe
heterogeneity. When heterogeneity was present, we repeated the
analysis removing one study at time to assess the source of
heterogeneity.
Presence of publication bias was explored using funnel plots of effect
size against standard error.11
The software Review Manager (RevMan, version 5.0.16 for
Windows, Oxford, UK; The Cochrane Collaboration, 2008) supported
the analysis.
Results
Study identification and selection
We identified 1552 potentially relevant studies from the following
databases: 977 from EMBASE and 575 from MEDLINE. We
excluded 1526 studies after title and abstract screening using pre-
defined inclusion and exclusion criteria; the remaining 26 studies
were retrieved in full for detailed evaluation. Three additional
studies were identified through manual review of references. Of
the 29 retrieved studies, 15 were excluded for the following
reasons: 8 did not match inclusion criteria, 5 were editorial or nar-
rative review, and 2 reported duplicated data.12,13 Fourteen studies
were therefore included in this systematic review.14–27 The study
identification and selection progression is summarized in Figure 1.
Study characteristics
Baseline characteristics of patients included in the studies were
summarized in Table 1. All studies were written in English.
Studies ranged in size from 22823 to 614 000 patients,19 for a
total of 863 805 included patients. Three RCTs,14–16 three
cohort,17–19 and eight case–control studies20–27 were included
in our systematic review. Twelve studies, i.e. one RCT, three
cohort, and eight case–control studies, including 850 118 patients
assessed the effect of statins on the risk of VTE.16–27 Three
studies, i.e. two RCTs and one case–control study, including a
total 15 041 patients assessed the effect of fibrates on the risk of
VTE.14,15,22 One of these two RCTs including 5010 patients also
assessed the effect of niacin on the risk of VTE.14 Five studies
including 61 971 patients assessed, in addition to the effect of
statins, the effect of lipid-lowering drugs other than statins on
VTE risk without specifying which drug was used.17,20,21,25,26 We
found no studies that have assessed the effect of cholesterol
absorption inhibitors, bile acid sequestrants, or fish oil on the
risk of VTE.
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Study quality
Quality assessment items are summarized in Table 2. Two of the
three RCTs were of high quality, but the incidence of VTE was
not a primary endpoint in any of these studies.15,16 All three
cohort studies were of low quality. Four (50%) case–control
studies were of high quality.22,24,26,27
Statins
The use of statins was found to significantly decrease the risk of
VTE at random-effects model analysis (OR, 0.81; 95% CI, 0.66–
0.99, Figure 2). There was a very high heterogeneity among the
studies (I2 . 80%, P, 0.05), which was caused by the case–
control and cohort studies. Removing one study at time, no signifi-
cant modification of overall heterogeneity was identified. Among
cohort studies, the study by Smeeth et al.19 mainly contributed
to statistical heterogeneity. After exploring results and heterogen-
eity according to study designs, no significant differences were
noted in ORs and in I2 between cohort and case–control
studies (Figure 2). Funnel plot is shown in Figure 3, and shows no
indication of publication bias.
When we pooled data from the five high-quality studies, the OR
remained similar (OR, 0.75; 95% CI, 0.54–1.04, random-effects
model) with a persistent high heterogeneity (I2 .
80%).16,22,24,26,27 Only two studies provided adequate data on
the risk of PE alone16,24 and only three studies provided adequate
data on the risk of DVT alone.16,17,24 No significant differences
were detected when these studies were separately analysed (at
random-effects model: OR, 1.12; 95% CI, 0.63–1.99 for PE and
OR, 0.72; 95% CI, 0.50–1.03 for DVT). Two studies provided
data on unprovoked VTE events: at random-effects model, the
OR was 0.83 (95% CI, 0.56–1.25).16,27 A sensitivity analysis on
potential differences among statins and on potential dose-
dependent effects could not be performed, because adequate
data on pravastatin, rosuvastatin, and simvastatin were available
in only two, one, and one studies, respectively16,21,23.
Fibrates
The use of fibrates was found to increase the risk of VTE (OR,
1.66; 95% CI, 1.35–2.04, fixed-effects model, Figure 4). There
was no heterogeneity among the studies (I2 ¼ 0%). The analysis
was repeated using random-effects model and yielded similar
results (OR, 1.58; 95% CI, 1.23–2.02). The FIELD Study15 results
suggest that fenofibrates increase mainly PE risk. Given the
limited number of available studies and data, no sensitivity analysis
was possible on different outcomes (PE and DVT), type of fibrates,
and dosage.
Non-statin lipid-lowering drugs
Pooling data of studies reporting the risk of VTE in non-statin
lipid-lowering drugs users, we found no effect on the risk of VTE
(random-effects model, OR, 0.88; 95% CI, 0.72–1.07).17,20,21,25,26
The only study investigating niacin also failed to demonstrate an
effect on the risk of VTE.14
Discussion
This is to our knowledge the first systematic review and
meta-analysis that assessed the effect of lipid-lowering drugs on
the risk of VTE. The results of this study indicate that the use of
statins is associated with a reduced risk of VTE and that the use
Figure 1 Studies’ selection progression.
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Table 1 Baseline characteristics
Study Patients Objective diagnosis
(diagnostic tools if specified)
Previous VTE as
exclusion criteria
Study drugs Primary or secondary
prevention of CVD
Randomized Controlled Trials
The Coronary Drug Project
Research Group14
5011 (1103 in the clofibrate group, 1119 in the
niacin group, 2789 in the placebo group)
NA No Clofibrate 1.8 mg daily; Niacin 3.0 mg
daily; placebo
Secondary prevention
The FIELD Study
Investigators15
9795 (4895 in the fenofibrate arm, 4900 in the
placebo arm)
NA No Fenofibrate 200 mg daily vs. placebo
in type 2 diabetes patients not
taking statins
Primary and secondary
prevention
JUPITER Study, 200916 17 802 (8901 in each arm, rosuvastatin vs.
placebo)
Yes (venogram, US, lung angiography,
lung scan, CT scan)
No Rosuvastatin 20 mg daily vs. placebo Primary prevention
Cohort Studies
Ray et al.17 125 862 in the primary cohort; 89 508 women
in the secondary cohort
NA (registry code) Yes (within 36
months)
Statins and other lipid-lowering drugs
(not specified further)
NA (patients with a CV
event in the last 36
months excluded)
Herrington et al.18 2471 postmenopausal women receiving
estrogen/progesteron vs. placebo
NA Yes Statins (not specified further) Secondary prevention
Smeeth et al.19 614 000 (59 000 with a statin treatment,
555 000 no statin treatment)
NA (registry code) No Rosuvastatin 0.9%; simvastatin 39.0%;
atorvastatin 20.6%; pravastatin
5.3%; fluvastatin 1.0%; cerivastatin
0.5%; mixed use 32.7%
NA
Case–Control Studies
Yang et al.20 84 093 patients, of whom 72 cases of idiopathic
VTE (37 confirmed and 35 probable)
37/72 yes; 35/72 no Yes Statins and other lipid-lowering drugs
(not specified further)
NA
Doggen et al.21 465 postmenopausal women with VTE (348
DVT, 42 PE, 75 DVT þ PE) and 1962
controls
In 93% of cases (venogram, US, lung
angiography, lung scan, CT scan)
Yes Simvastatin and pravastatin; other
non-statin lipid-lowering drugs
NA
Freeman et al.23 76 VTE cases and 152 controls NA No Pravastatin Primary and secondary
prevention
Yang and Kao25 173 VTE cases and 546 matched controls Yes (venogram, US, lung angiography,
lung scan, CT scan)
Yes Lipid-lowering drugs (not specified
further)
NA
Huerta et al.24 6550 VTE cases (3544 DVT and 3006 PE) and
10 000 matched controls
NA (registry code) Yes Statins (not specified further) NA
Lacut et al.22 677 VTE cases and 677 matched controls Yes (US, lung scan, CT scan, lung
angiography)
Yes Statins and fibrates (not specified
further)
NA
Sørensen et al.27 5824 VTE cases (3823 DVT and 2001 PE) (2310
unprovoked DVT and 1056 unprovoked PE)
and 58240 population controls
NA (registry code) Yes Statins (not specified further) NA
Ramcharan et al.26 4538 VTE cases (2670 DVT, 1583 PE, 285
DVT þ PE) and 5914 matched controls
Yes (hospital code plus requested
evidence of an objective test)
Yes Simvastatin, atorvastatin, pravastatin,
rosuvastatin, fluvastatin, other
lipid-lowering drugs
NA
CT, computed tomography; CVD, cardiovascular disease; DVT, deep venous thrombosis; NA, not available; PE, pulmonary embolism; VTE, venous thromboembolism; US, ultrasonography.
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Table 2 Quality assessment
Study Study design Consecutive
patients
Control
group
Follow-up Quality
score
Duration
(months)
Lost to follow-up (%)
Randomized Controlled Trials
The Coronary Drug Project
Research Group14
RCT Yes Yes 74 7.4% clofibrate; 10.7% niacin; 8.0% placebo 3 (medium)
The FIELD Study
Investigators15
RCT Yes Yes 60 2.2 5 (high)
JUPITER study, 2009 RCT Yes Yes 22.8 0% 5 (high)
Cohort Studies
Ray et al.17 Retrospective cohort study Yes Yes 13.2–16.8 NA 2 (low)
Herrington et al.18 Prospective inception cohort study No Yes 49.2 NA 2 (low)
Smeeth et al.19 Retrospective population- based cohort study Yes Yes 52.8 NA 2 (low)
Case–Control Studies
Yang et al.20 Population-based retrospective case–control study No Yes 1 (low)
Doggen et al.21 Population-based case–control study No Yes 1 (low)
Lacut et al.13,22 Case–control study Yes Yes 2 (high)
Freeman et al.23 Case–control study No Yes 1 (low)
Huerta et al.24 Prospective cohort study with case–control analysis Yes Yes 2 (high)
Yang and Kao25 Case–control study No Yes 1 (low)
Ramcharan et al.26 Population-based case–control study No Yes 2 (high)
Sørensen et al.27 Population-based case–control study Yes Yes 2 (high)
NA, not available; RCT, randomized controlled trial.
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Figure 2 Odds ratio for the association between statins use and venous thromboembolism.
Figure 3 Funnel plot of studies on the association between statins use and venous thromboembolism.
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of fibrates is associated with an increased risk of VTE. No data are
available on the effects of other lipid-lowering drugs, with the
exception of a single study with niacin.
Statins are the best-studied and most powerful cholesterol-
lowering drugs.1,28 Their therapeutic benefits in reducing cardiovas-
cular risk are not completely explained by low-density lipoprotein
cholesterol lowering only, thus suggesting that other mechanisms
are involved.2 Several vascular protective effects of statins have
been shown: increased nitric oxide bioavailability, atherosclerotic
plaque stabilization, regulation of angiogenesis, reduction of the
inflammatory response, and antithrombotic properties.2,3 Down-
regulation of the blood coagulation cascade is probably the result
of a decreased tissue factor expression, which leads to reduced
thrombin generation.3 In fact, statins use has been associated with
the impairment of several coagulant reactions catalysed by thrombin,
such as fibrinogen cleavage. Evidence indicates that statins may
enhance the activity of the protein C anticoagulant pathway by
increasing thrombomodulin expression on endothelial cells.29 Inhi-
bition of isoprenylation of signalling proteins, a covalentmodification
essential for their interaction with cell membranes, is the probable
principalmechanism.3Moreover, an antiplatelet and a profibrinolytic
effect of statins have been reported.30
All such properties of statins may support their potential effect
also in the prevention of VTE. Based on the results of our
meta-analysis including more than 850 000 patients, statins consist-
ently reduce the risk of VTE by approximately 20%. This obser-
vation carries some important implications. First, there is now a
clear need for a RCT primarily designed to evaluate the effects
of statin use in patients at high risk for VTE, such as patients
with previous VTE.16,31 Second, VTE should now be included as
a clinical endpoint in all new statins trials. Third, the claimed link
between atherosclerosis and VTE appears to be reinforced.32,33
Regardless of whether the beneficial effect of statins on the risk
of VTE is simply due to lipid lowering or to their influence on
thrombosis and inflammation, statins have the potential to be
active on both cardiovascular and venous thromboembolic
diseases.33,34
Fibrates, peroxisome proliferator-activated receptor-a activa-
tors, have been shown in some studies to diminish the procoagu-
lant activity and to stimulate fibrinolysis.35 Fibrates may also
increase plasma clot permeability and susceptibility to fibrinolysis
in coronary artery disease patients.35 No relevant influence on
platelet function, but increased homocysteine levels, has been
reported on fibrates treatment.22,36 Although fibrates potentially
have an overall antithrombotic effect, published data suggest an
increased risk for VTE. The reason for this observation remains
unclear, and the increase in homocysteine levels remains the
only available, albeit insufficient, explanation.22 Well-designed in
vitro and in vivo studies are thus now strongly encouraged, and
also new clinical studies with fibrates should systematically
include VTE events among major endpoints.
The main strengths of our review include the systematic
approach, the quality assessment of the literature, and the large
number of patients included. Conversely, our systematic review
has several potential limitations. First, our meta-analysis was
almost restricted to observational studies, mainly case–control
studies, and the application of formal meta-analytic methods to
observational studies is controversial, since bias implicit in the
study design may misrepresent the strength of associations
within the data.7,37 However, before pooling all data together,
we have provided separate analysis for cohort studies, case–
control studies, and RCTs when available. The study design does
not appear as the main reason for heterogeneity and the ORs
from different study designs remain very similar. Second, studies
included in our meta-analysis have different inclusion and exclusion
criteria, and to combine results across studies may be inappropri-
ate. However, when we repeated the analysis using a
random-effects model, an approach that accounts for some of
the variance between studies, we found similar results. Third, as
an intrinsic limit of meta-analyses, our meta-analysis was by neces-
sity restricted to single risk factors. Therefore, the distinct possi-
bility exists that the strength of association may be weaker with
a multifactorial regression analysis, given that it was not possible
to adjust or stratify for potential confounders. In particular, the
Figure 4 Odds ratio for the association between fibrates use and venous thromboembolism.
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effect of cardiovascular risk factors and a healthy user effect should
be considered.33 Fourth, given the mean low quality of the studies
included in our systematic review, our findings should be inter-
preted with caution. In particular, all three included RCTs had
VTE as a secondary outcome only. Fifth, due to limited available
published data, we cannot explore whether VTE risk reduction
is a class-effect or a molecule-effect of statins. Finally, since
there were too few studies evaluating the effects of fibrates, the
presence of publication bias could not be evaluated. Moreover, a
plausible biological rationale is lacking. However, given the magni-
tude of the association and the homogeneity of the results in the
selected studies, it is extremely unlikely that unpublished studies
with different results, if really exist, could substantially modify
our findings.
In conclusion, the use of statins may reduce the risk of VTE,
whereas the use of fibrates may increase this risk. Before clinical
implications of our findings can be discussed, RCTs evaluating
the effect of statins in patients at high risk of VTE are warranted.
Future prospective studies carefully investigating the underlying
mechanisms of the effects of lipid-lowering drugs on haemostasis
are strongly encouraged, in particular to assess the negative
effects of fibrates.
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